[Exclusive] Sunlant Bioengineering Received A Few Millions Dollars Backing From GP Capital

According to VCBeat, on June 13, 2019, Sunlant Bioengineering got a few million dollars from GP Capital in financing. This round of financing would be used to build the new production facility in Wuxi and accelerate the development of its new products.

Sunlant Bioengineering is the first company in the world to specialize in the application of CLIA, multi-index parallel detection and full-automatic protein chip analysis technologies for the systematic detection of serious diseases. The output of the very first fully automated analytical system for the protein biochip has filled the gap in the multi-index detection field. The product has covered many AAA hospitals and health check-up institutions, breaking the long-term foreign product monopoly and technology blockade in the field of high technological detection.

In this field, Sunlant Bioengineering has developed detection products for tumor markers, cardiovascular and cerebrovascular diseases, heart failure, infections, allergens and autoimmune diseases. According to the person in charge of Sunlant Bioengineering, the microarray chemiluminescent protein chip technology platform has High-throughput, high-accuracy, high-speed and low-cost features that can greatly improve the detection rate of diseases.

Sunlant Bioengineering combines protein chip technology with chemiluminescence technology to launch the first "automated hard matrix microarray chemiluminescent protein chip detection system", which fills the gap in the field of multi-indicator joint detection biochips. The product has been on the market for less than three years and has been widely used in nearly 400 hospitals and medical examination institutions throughout the country.

Established by SIG in July 2009, GP Capital is an investment company strategically held by SIG, relatively controlled by SIG Asset Management.